PL2233156T3 - Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych - Google Patents

Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych

Info

Publication number: PL2233156T3
Authority: PL; Poland
Prior art keywords: carriers; pharmaceutical conjugates; aprotinin polypeptides; aprotinin; polypeptides
Prior art date: 2005-07-15

Application number

PL10006638T

Other languages

English (en)

Inventor

Richard Beliveau

Michel Demeule

Christian Che

Anthony Regina

Original Assignee

Angiochem Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-15

Filing date

2006-07-14

Publication date

2013-09-30

2006-07-14 Application filed by Angiochem Inc filed Critical Angiochem Inc

2013-09-30 Publication of PL2233156T3 publication Critical patent/PL2233156T3/pl

Links

108010039627 Aprotinin Proteins 0.000 title 1
229960004405 aprotinin Drugs 0.000 title 1
239000000969 carrier Substances 0.000 title 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL10006638T 2005-07-15 2006-07-14 Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych PL2233156T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US69937505P	2005-07-15	2005-07-15
US75853206P	2006-01-13	2006-01-13
EP06761127A EP1907009A4 (en)	2005-07-15	2006-07-14	USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES
EP10006638.0A EP2233156B1 (en)	2005-07-15	2006-07-14	Use of aprotinin polypeptides as carriers in pharmaceutical conjugates

Publications (1)

Publication Number	Publication Date
PL2233156T3 true PL2233156T3 (pl)	2013-09-30

Family

ID=37668389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10006638T PL2233156T3 (pl)	2005-07-15	2006-07-14	Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych

Country Status (15)

Country	Link
US (3)	US8969310B2 (pl)
EP (4)	EP2471555A3 (pl)
JP (3)	JP5436856B2 (pl)
CN (1)	CN101262890B (pl)
AU (1)	AU2006272405B2 (pl)
BR (1)	BRPI0613005A8 (pl)
CA (1)	CA2614687C (pl)
DK (2)	DK2233156T3 (pl)
ES (2)	ES2424242T3 (pl)
HR (1)	HRP20130720T1 (pl)
PL (1)	PL2233156T3 (pl)
PT (1)	PT2233156E (pl)
RU (2)	RU2422143C2 (pl)
SI (1)	SI2233156T1 (pl)
WO (1)	WO2007009229A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2368941T3 (es)	2003-01-06	2011-11-23	Angiochem Inc.	Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
CA2589860A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
RU2408605C2 (ru)	2005-02-18	2011-01-10	Анджиокем Инк.	Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
US20090016959A1 (en) *	2005-02-18	2009-01-15	Richard Beliveau	Delivery of antibodies to the central nervous system
PL2233156T3 (pl)	2005-07-15	2013-09-30	Angiochem Inc	Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
AU2006283726C1 (en)	2005-08-24	2015-05-07	Immunogen, Inc.	Process for preparing maytansinoid antibody conjugates
EP2074142A4 (en)	2006-10-19	2010-10-27	Angiochem Inc	COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5844971B2 (ja) *	2007-05-29	2016-01-20	アンジオケム，インコーポレーテッド	コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド
CN101815724B (zh) *	2007-05-29	2015-02-25	安吉奥开米公司	用于将轭合至其的试剂递送至组织的抑肽酶样多肽
CA2709635A1 (en) *	2007-12-20	2009-07-02	Angiochem Inc.	Polypeptide-nucleic acid conjugates and uses thereof
EP2261254A3 (en)	2007-12-21	2011-04-13	Amgen, Inc	Anti-amyloid antibodies and uses thereof
JP5860698B2 (ja) *	2008-04-18	2016-02-16	アンジオケム，インコーポレーテッド	パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
EP2346906A4 (en) *	2008-10-15	2013-04-24	Angiochem Inc	CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5705118B2 (ja)	2008-10-15	2015-04-22	アンジオケムインコーポレーテッド	薬物送達のためのエトポシドおよびドキソルビシン複合体
JP5759379B2 (ja) *	2008-12-05	2015-08-05	アンジオケムインコーポレーテッド	ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010069074A1 (en)	2008-12-17	2010-06-24	Universite Du Quebec A Montreal	Membrane type-1 matrix metalloprotein inhibitors and uses thereof
DE102009006228A1 (de)	2009-01-27	2010-07-29	Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh	Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen
JP2010229122A (ja) *	2009-03-06	2010-10-14	Kumamoto Univ	抗癌剤、医薬、及び癌疾患の検査薬
EP2421562B1 (en)	2009-04-20	2019-03-13	Angiochem Inc.	Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2011012794A (es)	2009-06-03	2012-05-08	Immunogen Inc	Metodos de conjugacion.
RU2012103240A (ru)	2009-07-02	2013-08-10	Ангиокем Инк.	Мультимерные пептидные конъюгаты и их применение
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2012037687A1 (en) *	2010-09-23	2012-03-29	Angiochem Inc.	Therapeutic polypeptides and uses thereof
CN102085157B (zh) *	2011-01-27	2012-02-01	中国水产科学研究院黄海水产研究所	扇贝抗氧化肽纳米脂质体及其制备方法
CN102614524A (zh) *	2011-02-01	2012-08-01	复旦大学	低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
ME03353B (me)	2011-03-29	2019-10-20	Immunogen Inc	Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
EP2885318A4 (en)	2012-08-14	2016-03-30	Angiochem Inc	PEPTIDE DENDRIMER CONJUGATES AND ITS USES
WO2014055877A1 (en) *	2012-10-04	2014-04-10	Immunogen, Inc.	Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
MX377795B (es) *	2012-11-12	2025-03-11	Angiochem Inc	Conjugados de polipeptido derivado de aprotinina-anticuerpo.
WO2015002486A1 (ko)	2013-07-03	2015-01-08	서울대학교산학협력단	시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
WO2015002903A1 (en)	2013-07-03	2015-01-08	Arizona Board Of Regents For The University Of Arizona	Method for treating cognitive dysfunction
US10183055B2 (en)	2014-07-21	2019-01-22	Arizona Board Of Regents On Behalf Of The University Of Arizona	Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
JP6666899B2 (ja)	2014-07-21	2020-03-18	アリゾナボードオブリージェンツオンビハーフオブザユニヴァーシティーオブアリゾナ	Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
GB201502447D0 (en)	2015-02-13	2015-04-01	Univ Liverpool	Method and apparatus for sample analysis
CA2989400A1 (en)	2015-06-15	2016-12-22	Angiochem Inc.	Ang1005 for the treatment of leptomeningeal carcinomatosis
WO2019148181A1 (en)	2018-01-29	2019-08-01	Cognos Therapeutics, Inc.	Intratumoral delivery of bortezomib
CN111529716B (zh) *	2020-06-02	2021-05-28	南方医科大学	一种多肽-紫杉醇偶联物及其应用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US508697A (en) *		1893-11-14		Jar or bottle receiver
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
ES8407536A1 (es) *	1983-10-07	1984-10-01	Jumberca Sa	Mejoras en los alimentadores de hilo para telares circulares de genero de punto dotados de dispositivos listadores.
WO1987005702A1 (en)	1986-03-13	1987-09-24	Biotechnology Australia Pty. Ltd.	Method of assay of inhibin
US4902505A (en)	1986-07-30	1990-02-20	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en)	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en)	1987-08-04	1990-02-27	Bristol-Myers Company	Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en)	1987-08-07	1989-04-05	Bayer Ag	Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en)	1988-03-07	1990-07-17	The United States Of America As Represented By The Department Of Health And Human Services	Water soluble, antineoplastic derivatives of taxol
US5632990A (en)	1988-04-22	1997-05-27	Cancer Research Campaign Tech. Ltd.	Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en)	1988-05-16	1993-11-02	Vestar, Inc.	Liposome targeting using receptor specific ligands
US5028697A (en)	1988-08-08	1991-07-02	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en)	1988-08-15	1992-12-08	Neorx Corporation	Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5948634A (en)	1988-12-21	1999-09-07	The General Hospital Coporation	Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de)	1989-04-18	1990-10-31	Bayer Ag	Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en)	1989-06-30	2000-02-01	Bristol-Myers Squibb Company	Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en)	1990-05-17	2002-11-05	Dana-Farber Cancer Institute, Inc.	Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en)	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US6495513B1 (en)	1991-03-11	2002-12-17	Curis, Inc.	Morphogen-enhanced survival and repair of neural cells
US5955444A (en)	1991-08-09	1999-09-21	Massachusetts Institute Of Technology	Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en)	1991-12-13	1997-05-06	Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
GB9213077D0 (en)	1992-06-19	1992-08-05	Erba Carlo Spa	Polymerbound taxol derivatives
WO1994007528A1 (en)	1992-09-25	1994-04-14	Corvas International, Inc.	Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex
EP0599303A3 (en)	1992-11-27	1998-07-29	Takeda Chemical Industries, Ltd.	Peptide conjugate
MX9307777A (es)	1992-12-15	1994-07-29	Upjohn Co	7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
WO1994019692A1 (en)	1993-02-18	1994-09-01	The General Hospital Corporation	Alzheimer's disease therapeutics
WO1996031531A2 (en)	1995-04-04	1996-10-10	Advanced Bioconcept, Inc.	Fluorescent peptides
WO1996035788A2 (en)	1995-05-08	1996-11-14	Scios, Inc.	Kunitz type protease inhibitors
ZA963619B (en)	1995-05-08	1996-11-22	Scios Inc	Protease inhibitor peptides
WO1996039183A1 (en)	1995-05-31	1996-12-12	Fred Hutchinson Cancer Research Center	Compositions and methods for targeted delivery of effector molecules
US5780265A (en)	1995-06-05	1998-07-14	Genentech, Inc.	Kunitz type plasma kallikrein inhibitors
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
EP0831880A4 (en)	1995-06-07	2004-12-01	Imclone Systems Inc	ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
AU716923B2 (en)	1996-03-11	2000-03-09	Aerovance, Inc.	Human bikunin
AU2409397A (en)	1996-04-24	1997-11-12	Rijksuniversiteit Te Groningen	A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein
WO1997040854A2 (en)	1996-05-01	1997-11-06	Antivirals Inc.	Polypeptide conjugates for transporting substances across cell membranes
JP2001503396A (ja)	1996-10-11	2001-03-13	アルザコーポレイション	治療用リポソーム組成物および方法
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
US5948750A (en)	1996-10-30	1999-09-07	Merck & Co., Inc.	Conjugates useful in the treatment of prostate cancer
JP4116683B2 (ja)	1997-02-28	2008-07-09	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	徐放性局所送達製剤
IL131655A0 (en) *	1997-03-04	2001-01-28	Bio Technology General Corp	Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
US6126965A (en)	1997-03-21	2000-10-03	Georgetown University School Of Medicine	Liposomes containing oligonucleotides
IL132941A0 (en)	1997-05-21	2001-03-19	Univ Leland Stanford Junior	Composition and method for enhancing transport across biological membranes
US6391305B1 (en)	1997-09-10	2002-05-21	Merck & Co., Inc.	Conjugates useful in the treatment of prostate cancer
US6093692A (en)	1997-09-25	2000-07-25	The University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en)	1997-11-18	2002-11-05	Canji Inc	Purging of stem cell products
WO1999026657A1 (en)	1997-11-25	1999-06-03	Musc Foundation For Research Development	Inhibitors of nitric oxide synthase
US5981564A (en)	1998-07-01	1999-11-09	Universite Laval	Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) *	1998-07-03	1998-09-02	Cyclacel Ltd	Delivery system
US6703381B1 (en)	1998-08-14	2004-03-09	Nobex Corporation	Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) *	1998-10-02	1999-07-13	Abbott Laboratories	Pharmaceutical compositions containing paclitaxel
US6191290B1 (en)	1999-02-24	2001-02-20	Uab Research Foundation	Taxane derivatives for targeted therapy of cancer
US6713454B1 (en)	1999-09-13	2004-03-30	Nobex Corporation	Prodrugs of etoposide and etoposide analogs
US6136846A (en)	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
DE19953696A1 (de) *	1999-11-09	2001-05-10	Alexander Cherkasky	Selektive proteolytische Synzyme (SPS)
CA2307393A1 (en) *	2000-05-01	2001-11-01	The University Of British Columbia	Ginsenoside chemotherapy
CA2355334A1 (en)	2000-10-16	2002-04-16	Procyon Biopharma Inc.	Pharmaceutical preparations and methods for inhibiting tumors
US6919370B2 (en)	2000-11-28	2005-07-19	Transform Pharmaceuticals, Inc.	Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002076448A1 (en)	2001-03-23	2002-10-03	Napro Biotherapeutics, Inc.	Molecular conjugates for use in treatment of cancer
DK2322631T3 (en)	2001-04-19	2015-01-12	Scripps Research Inst	Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
EP2147679B1 (en) *	2001-07-25	2014-06-25	Raptor Pharmaceutical, Inc.	Compositions for blood-brain barrier transport
US20040161776A1 (en)	2001-10-23	2004-08-19	Maddon Paul J.	PSMA formulations and uses thereof
US7192921B2 (en)	2001-11-08	2007-03-20	The Burnham Institute	Peptides that home to tumor lymphatic vasculature and methods of using same
CA2470826A1 (en) *	2001-12-20	2003-07-03	Bristol-Myers Squibb Company	Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
RU2196604C1 (ru) *	2001-12-21	2003-01-20	Северин Евгений Сергеевич	Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
ATE365213T1 (de) *	2002-02-07	2007-07-15	Yissum Res Dev Co	Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
US6881829B2 (en)	2002-04-26	2005-04-19	Chimeracom, L.L.C.	Chimeric hybrid analgesics
WO2004003145A2 (en)	2002-06-28	2004-01-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en)	2002-11-26	2010-11-09	Medtronic, Inc.	Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en)	2002-11-27	2004-05-27	The Regents Of The University Of California	Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en)	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
ES2368941T3 (es)	2003-01-06	2011-11-23	Angiochem Inc.	Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
KR101184833B1 (ko) *	2003-04-08	2012-09-20	바이오템프트, 비.브이.	Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
JP4703566B2 (ja)	2003-05-14	2011-06-15	イムノゲンインコーポレーティッド	薬剤複合体組成物
AU2003286870A1 (en)	2003-06-05	2005-01-04	Salk Institute For Biological Studies	Targeting polypeptides to the central nervous system
WO2005002515A2 (en)	2003-06-20	2005-01-13	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en)	2003-06-20	2005-02-03	Biomarin Pharmaceutical Inc.	Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7927811B2 (en)	2003-08-08	2011-04-19	Proteus Sciences Co., Ltd.	Polypeptides having brain-localizing activity and uses thereof
JP2007512001A (ja) *	2003-08-28	2007-05-17	バイオレクシスファーマシューティカルコーポレイション	Ｅｐｏミメティックペプチドおよび融合タンパク質
US20050058702A1 (en)	2003-09-17	2005-03-17	Ben-Sasson Shmuel A.	Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en)	2003-11-20	2005-09-22	Angiotech International Ag	Polymer compositions and methods for their use
US7208174B2 (en)	2003-12-18	2007-04-24	Hoffmann-La Roche Inc.	Liposome compositions
US7638299B2 (en)	2004-07-21	2009-12-29	Ambrx, Inc.	Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006010891A2 (en)	2004-07-26	2006-02-02	Asterion Limited	Linkers
CA2580189C (en)	2004-09-29	2013-05-21	Children's Memorial Hospital	Sirna-mediated gene silencing of alpha synuclein
US20090016959A1 (en)	2005-02-18	2009-01-15	Richard Beliveau	Delivery of antibodies to the central nervous system
RU2408605C2 (ru)	2005-02-18	2011-01-10	Анджиокем Инк.	Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
NZ595313A (en)	2005-02-18	2013-03-28	Abraxis Bioscience Llc	The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2616906A1 (en)	2005-05-12	2006-11-23	Tapestry Pharmaceuticals, Inc.	Molecular constructs suitable for targeted conjugates
WO2006138343A2 (en)	2005-06-14	2006-12-28	Raptor Pharmaceutical Inc.	Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
PL2233156T3 (pl)	2005-07-15	2013-09-30	Angiochem Inc	Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
KR20080042804A (ko)	2005-07-19	2008-05-15	더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이	뇌혈관장벽을 통하여 뇌 암세포 내로 침투하는 운반제 및이의 이용 방법
GB0517092D0 (en)	2005-08-19	2005-09-28	Novartis Ag	New compositions containing taxane derivatives
EP1934359A2 (en)	2005-09-08	2008-06-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US9062126B2 (en)	2005-09-16	2015-06-23	Raptor Pharmaceuticals Inc.	Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US8142781B2 (en)	2005-10-07	2012-03-27	Armagen Technologies, Inc.	Fusion proteins for blood-brain barrier delivery
CA2627585A1 (en)	2005-11-01	2007-05-10	Alnylam Pharmaceuticals, Inc.	Rnai inhibition of influenza virus replication
AR054215A1 (es)	2006-01-20	2007-06-13	Eriochem Sa	Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
ATE524493T1 (de)	2006-07-24	2011-09-15	Biorexis Pharmaceutical Corp	Exendin-fusionsproteine
CN101594878A (zh)	2006-09-18	2009-12-02	雷普特药品公司	通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
EP2074142A4 (en)	2006-10-19	2010-10-27	Angiochem Inc	COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
CN101815724B (zh)	2007-05-29	2015-02-25	安吉奥开米公司	用于将轭合至其的试剂递送至组织的抑肽酶样多肽
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en)	2007-09-17	2014-08-12	Ludwig Institute For Cancer Research Ltd.	Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en)	2007-11-26	2009-06-04	Armagen Technologies, Inc.	Fusion proteins for delivery of gdnf to the cns
CA2709635A1 (en)	2007-12-20	2009-07-02	Angiochem Inc.	Polypeptide-nucleic acid conjugates and uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11260133B2 (en)	2008-02-21	2022-03-01	Sanford-Burnham Medical Research Institute	Methods and compositions related to peptides and proteins with C-terminal elements
JP5860698B2 (ja)	2008-04-18	2016-02-16	アンジオケム，インコーポレーテッド	パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
EP2346906A4 (en)	2008-10-15	2013-04-24	Angiochem Inc	CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5705118B2 (ja) *	2008-10-15	2015-04-22	アンジオケムインコーポレーテッド	薬物送達のためのエトポシドおよびドキソルビシン複合体
JP5759379B2 (ja)	2008-12-05	2015-08-05	アンジオケムインコーポレーテッド	ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20110288009A1 (en)	2008-12-05	2011-11-24	Angiochem Inc.	Leptin and leptin analog conjugates and uses thereof
BRPI0923283A2 (pt)	2008-12-05	2017-06-06	Angiochem Inc	conjugados terapêuticos de peptídeo e usos dos mesmos
WO2010069074A1 (en)	2008-12-17	2010-06-24	Universite Du Quebec A Montreal	Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (en) *	2009-04-20	2019-03-13	Angiochem Inc.	Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en)	2009-05-08	2010-11-11	Temple University - Of The Commonwealth System Of Higher Education	Targeted nanoparticles for intracellular cancer therapy
US20120196803A1 (en)	2009-06-11	2012-08-02	Angiochem Inc.	Fusion proteins for delivery of gdnf and bdnf to the central nervous system
RU2012103240A (ru)	2009-07-02	2013-08-10	Ангиокем Инк.	Мультимерные пептидные конъюгаты и их применение
PL2453923T3 (pl)	2009-07-14	2016-06-30	Mayo Found Medical Education & Res	Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
US20120277158A1 (en)	2009-10-06	2012-11-01	Angiochem Inc.	Compositions and methods for the transport of therapeutic agents
US8530429B2 (en)	2009-11-24	2013-09-10	Arch Cancer Therapeutics, Inc.	Brain tumor targeting peptides and methods
WO2011153642A1 (en)	2010-06-10	2011-12-15	Angiochem Inc.	Leptin and leptin analog conjugates and fusion proteins and uses thereof
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2012037687A1 (en)	2010-09-23	2012-03-29	Angiochem Inc.	Therapeutic polypeptides and uses thereof
RU2013127625A (ru)	2010-11-18	2014-12-27	Зе Дженерал Хоспитал Корпорейшен	Новые композиции и применения антигипертензивных средств для терапии рака
WO2013056096A1 (en)	2011-10-13	2013-04-18	Angiochem Inc.	Polypeptide-opioid conjugates and uses thereof
MX2014006594A (es)	2011-12-01	2015-09-16	Angiochem Inc	Compuestos de enzimas lisosomales apuntados.
EP2785837A4 (en)	2011-12-01	2015-07-01	Angiochem Inc	TARGETED ENZYMATIC COMPOUNDS AND ITS USES
MX2014015551A (es)	2012-06-15	2016-09-19	Angiochem Inc	Compuestos iduronidasa apuntados.
EP2885318A4 (en)	2012-08-14	2016-03-30	Angiochem Inc	PEPTIDE DENDRIMER CONJUGATES AND ITS USES
AU2013302273A1 (en)	2012-08-14	2015-02-19	Angiochem Inc.	Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
MX377795B (es)	2012-11-12	2025-03-11	Angiochem Inc	Conjugados de polipeptido derivado de aprotinina-anticuerpo.
GB201220474D0 (en)	2012-11-14	2012-12-26	Sagetis Biotech Sl	Polypeptides
WO2014082184A1 (en)	2012-11-30	2014-06-05	Angiochem Inc.	Targeted iduronate-2-sulfatase compounds
HK1179821A2 (en)	2013-05-28	2013-10-04	捷迅视讯器材有限公司	High voltage discharge protection device and radio frequency transmission apparatus using the same
WO2014194429A1 (en)	2013-06-06	2014-12-11	Angiochem Inc.	Targeted enzyme compounds and uses thereof
WO2014194428A1 (en)	2013-06-06	2014-12-11	Angiochem Inc.	Targeted heparan sulfatase compounds

2006
- 2006-07-14 PL PL10006638T patent/PL2233156T3/pl unknown
- 2006-07-14 CA CA2614687A patent/CA2614687C/en not_active Expired - Fee Related
- 2006-07-14 JP JP2008520685A patent/JP5436856B2/ja not_active Expired - Fee Related
- 2006-07-14 BR BRPI0613005A patent/BRPI0613005A8/pt not_active Application Discontinuation
- 2006-07-14 DK DK10006638.0T patent/DK2233156T3/da active
- 2006-07-14 CN CN200680033365.8A patent/CN101262890B/zh not_active Expired - Fee Related
- 2006-07-14 ES ES10006638T patent/ES2424242T3/es active Active
- 2006-07-14 EP EP11010071A patent/EP2471555A3/en not_active Withdrawn
- 2006-07-14 ES ES11010125T patent/ES2744225T3/es active Active
- 2006-07-14 WO PCT/CA2006/001165 patent/WO2007009229A1/en not_active Ceased
- 2006-07-14 AU AU2006272405A patent/AU2006272405B2/en not_active Ceased
- 2006-07-14 EP EP06761127A patent/EP1907009A4/en not_active Withdrawn
- 2006-07-14 RU RU2008105677/15A patent/RU2422143C2/ru active
- 2006-07-14 EP EP10006638.0A patent/EP2233156B1/en not_active Not-in-force
- 2006-07-14 PT PT100066380T patent/PT2233156E/pt unknown
- 2006-07-14 EP EP11010125.0A patent/EP2433653B1/en active Active
- 2006-07-14 SI SI200631629T patent/SI2233156T1/sl unknown
- 2006-07-14 DK DK11010125.0T patent/DK2433653T3/da active
2007
- 2007-05-30 US US11/807,917 patent/US8969310B2/en active Active
2011
- 2011-04-19 RU RU2011115418/15A patent/RU2011115418A/ru not_active Application Discontinuation
2012
- 2012-10-18 JP JP2012230853A patent/JP2013047249A/ja not_active Withdrawn
2013
- 2013-08-01 HR HRP20130720TT patent/HRP20130720T1/hr unknown
2015
- 2015-03-02 US US14/635,856 patent/US9713646B2/en not_active Expired - Fee Related
- 2015-06-03 JP JP2015112969A patent/JP2015163641A/ja active Pending
2017
- 2017-06-30 US US15/639,758 patent/US20180221497A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BRPI0613005A8 (pt)	2017-12-26
RU2008105677A (ru)	2009-08-20
JP5436856B2 (ja)	2014-03-05
US20090082277A1 (en)	2009-03-26
US20180221497A1 (en)	2018-08-09
EP2433653B1 (en)	2019-06-05
AU2006272405B2 (en)	2013-02-07
US8969310B2 (en)	2015-03-03
HRP20130720T1 (en)	2013-09-30
EP2471555A2 (en)	2012-07-04
JP2013047249A (ja)	2013-03-07
CA2614687A1 (en)	2007-01-25
EP2233156A2 (en)	2010-09-29
EP1907009A1 (en)	2008-04-09
CA2614687C (en)	2016-03-22
ES2424242T3 (es)	2013-09-30
DK2433653T3 (da)	2019-08-19
US20150314010A1 (en)	2015-11-05
ES2744225T3 (es)	2020-02-24
PT2233156E (pt)	2013-07-31
CN101262890A (zh)	2008-09-10
BRPI0613005A2 (pt)	2010-12-14
WO2007009229A1 (en)	2007-01-25
JP2009500431A (ja)	2009-01-08
DK2233156T3 (da)	2013-08-05
EP1907009A4 (en)	2009-09-02
SI2233156T1 (sl)	2013-09-30
RU2422143C2 (ru)	2011-06-27
EP2233156A3 (en)	2010-10-13
AU2006272405A1 (en)	2007-01-25
RU2011115418A (ru)	2012-10-27
EP2471555A3 (en)	2012-10-17
EP2433653A1 (en)	2012-03-28
EP2233156B1 (en)	2013-05-01
JP2015163641A (ja)	2015-09-10
HK1148689A1 (en)	2011-09-16
CN101262890B (zh)	2015-08-26
US9713646B2 (en)	2017-07-25

Publication	Publication Date	Title
HRP20130720T1 (en)	2013-09-30	Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
PL1912671T3 (pl)	2018-02-28	Koniugaty beta-glukuronid-linker-lek
IL186959A0 (en)	2008-02-09	Peptides and pharmaceutical compositions containing the same
IL177480A0 (en)	2006-12-10	Pharmaceutical composition
ZA200708705B (en)	2009-12-30	Pharmaceutical composition
IL185308A0 (en)	2008-02-09	Replikin peptides and uses thereof
EP1976864A4 (en)	2010-09-01	NEW PEPTIDE AND ITS USE
IL221395A0 (en)	2012-09-24	Pharmaceutical compositions comprising alpha ketoamide derivatives and uses thereof
EP1890677A4 (en)	2013-01-30	PHARMACEUTICAL COMPOSITIONS AND THEIR USE
PL2046830T3 (pl)	2011-11-30	Polipeptydy CSF3R i ich zastosowania
GB0516069D0 (en)	2005-09-14	Pharmaceutical and use thereof
HU0401177D0 (en)	2004-08-30	Pharmaceutical composition
GB0621513D0 (en)	2006-12-06	Novel polypeptides and uses thereof
GB0404420D0 (en)	2004-03-31	Pharmaceutical composition
GB0607798D0 (en)	2006-05-31	Novel polypeptides and use thereof
GB0425255D0 (en)	2004-12-15	Pharmaceutical composition
ZA200701932B (en)	2008-08-27	Pharmaceutical composition
ZA200701931B (en)	2008-10-29	Pharmaceutical composition
GB0526120D0 (en)	2006-02-01	Therapeutic peptides
GB0517043D0 (en)	2005-09-28	Improvements in pharmaceutical compositions
GB0512246D0 (en)	2005-07-27	Novel pharmaceutical
GB0516571D0 (en)	2005-09-21	Novel polypeptides and uses thereof
GB0515573D0 (en)	2005-09-07	Improvements in pharmaceutical compositions
GB0508767D0 (en)	2005-06-08	Pharmaceutical preparations and their uses
ZA200800392B (en)	2009-04-29	Pharmaceutical composition